Dulce-Iliana Navarro-Vergara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dulce-Iliana Navarro-Vergara has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Guillermo Cueto-Robledo
Pulmonary Circulation Clinic, Hospital General de México 'Dr. Eduardo Liceaga', 06720, Mexico City, Mexico; Cardiorespiratory emergencies, General Hospital of México, Dr. Eduardo Liceaga, 06720, Mexico City, Mexico; Faculty of Medicine, National Autonomous University of Mexico, 04510, Mexico City, Mexico
7 shared publications - Ernesto Roldan-Valadez
Division of Research, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, 14389, Mexico City, Mexico; I.M. Sechenov First Moscow State Medical University (Sechenov University), Department of Radiology, 119992, Moscow, Russia
5 shared publications - Maria-Berenice Torres-Rojas
Pulmonary Circulation Clinic, Hospital General de México 'Dr. Eduardo Liceaga', 06720, Mexico City, Mexico; Cardiorespiratory emergencies, General Hospital of México, Dr. Eduardo Liceaga, 06720, Mexico City, Mexico
5 shared publications - Marisol Garcia-Cesar
Pulmonary Circulation Clinic, Hospital General de México 'Dr. Eduardo Liceaga', 06720, Mexico City, Mexico; Cardiorespiratory emergencies, General Hospital of México, Dr. Eduardo Liceaga, 06720, Mexico City, Mexico
5 shared publications - Galileo Escobedo
Laboratorio de Inmunometabolismo, División de Investigación, Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico
3 shared publications - Leslie-Marisol Gonzalez-Hermosillo
Programa de Doctorado en Ciencias Biomédicas, Unidad de Posgrado, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico
3 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6913
Methylation in the TAC1 Gene Promoter Is Associated with the Transition from Acute Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension
Emerging evidence suggests that deoxyribonucleic acid (DNA) methylation may be linked to progression from acute pulmonary embolism (APE) to chronic thromboembolic pulmonary hypertension (CTEPH), especially in genes regulating vascular tone. We investigated the association between tachykinin precursor 1 (TAC1) promoter methylation and the APE-to-CTEPH transition in a 6-month ambispective cohort study of 110 patients with confirmed APE. We recorded clinical, laboratory, and hemodynamic parameters at hospital admission and collected 4 mL of peripheral blood for DNA extraction. We quantified the percentage of TAC1 promoter methylation using bisulfite conversion and methylation-specific polymerase chain reaction (PCR), also assessing TAC1 gene expression by quantitative PCR. During the 6-month follow-up, 7.2% of patients developed CTEPH. Patients who later progressed to CTEPH had a significant 0.4-fold increase in TAC1 promoter methylation compared to those who did not. Increased methylation was associated with a 1.5-fold decrease in TAC1 gene expression in whole-blood leukocytes from CTEPH patients. TAC1 methylation significantly correlated with mixed venous oxygen saturation (SvO2), D-dimer, and B-type natriuretic peptide concentrations. TAC1 promoter hypermethylation is associated with progression from APE to CTEPH and concurs with TAC1 gene repression, probably compromising systemic oxygenation, thrombus resolution, and cardiac strain.
- 1 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (15) , 6913
Open AccessMethylation in the TAC1 Gene Promoter Is Associated with the Transition from Acute Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension
Emerging evidence suggests that deoxyribonucleic acid (DNA) methylation may be linked to progression from acute pulmonary embolism (APE) to chronic thromboembolic pulmonary hypertension (CTEPH), especially in genes regulating vascular tone. We investigated the association between tachykinin precursor 1 (TAC1) promoter methylation and the APE-to-CTEPH transition in a 6-month ambispective cohort study of 110 patients with confirmed APE. We recorded clinical, laboratory, and hemodynamic parameters at hospital admission and collected 4 mL of peripheral blood for DNA extraction. We quantified the percentage of TAC1 promoter methylation using bisulfite conversion and methylation-specific polymerase chain reaction (PCR), also assessing TAC1 gene expression by quantitative PCR. During the 6-month follow-up, 7.2% of patients developed CTEPH. Patients who later progressed to CTEPH had a significant 0.4-fold increase in TAC1 promoter methylation compared to those who did not. Increased methylation was associated with a 1.5-fold decrease in TAC1 gene expression in whole-blood leukocytes from CTEPH patients. TAC1 methylation significantly correlated with mixed venous oxygen saturation (SvO2), D-dimer, and B-type natriuretic peptide concentrations. TAC1 promoter hypermethylation is associated with progression from APE to CTEPH and concurs with TAC1 gene repression, probably compromising systemic oxygenation, thrombus resolution, and cardiac strain.
- 3 April 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (8) , 103337
Management of pulmonary arterial hypertension with intermediate-high-risk pulmonary embolism during pregnancy: Diagnostic challenges, catheter-directed thrombolysis, and intravenous treprostinil — A narrative review with an institutional case snapshot
- 3 April 2026
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (8) , 103337
Management of pulmonary arterial hypertension with intermediate-high-risk pulmonary embolism during pregnancy: Diagnostic challenges, catheter-directed thrombolysis, and intravenous treprostinil — A narrative review with an institutional case snapshot
- Open Access
- 16 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Localized Pulmonary Amyloidosis Associated With Sjögren’s Syndrome, Coexisting Lymphoid Interstitial Pneumonia, and a Severe Double Aortic Lesion: A Case Report and Literature Review
Amyloidosis is a protein-folding disease that results in the deposition of misfolded proteins into various tissues of the body, resulting in dysfunction of the affected organ. It is caused by a heterogeneous group of disorders caused by extracellular deposition of misfolded proteins as insoluble fibrils. Involvement of the lungs can present as nodular, tracheobronchial, or diffuse interstitial, and can be mistaken for cancer or infection on imaging. The combination of Sjögren's syndrome, chronic activation of B cells, and the risk of developing a lymphoproliferative disorder can lead to the rare deposition of amyloid. In cystic lung disease, the amyloid deposition can be misattributed to lymphoid interstitial pneumonia (LIP).
- 16 February 2026
- Published by Springer Nature in Cureus
- Vol. 18 (2)
Open AccessLocalized Pulmonary Amyloidosis Associated With Sjögren’s Syndrome, Coexisting Lymphoid Interstitial Pneumonia, and a Severe Double Aortic Lesion: A Case Report and Literature Review
Amyloidosis is a protein-folding disease that results in the deposition of misfolded proteins into various tissues of the body, resulting in dysfunction of the affected organ. It is caused by a heterogeneous group of disorders caused by extracellular deposition of misfolded proteins as insoluble fibrils. Involvement of the lungs can present as nodular, tracheobronchial, or diffuse interstitial, and can be mistaken for cancer or infection on imaging. The combination of Sjögren's syndrome, chronic activation of B cells, and the risk of developing a lymphoproliferative disorder can lead to the rare deposition of amyloid. In cystic lung disease, the amyloid deposition can be misattributed to lymphoid interstitial pneumonia (LIP).
- 14 November 2025
- p. 103209
In situ Pulmonary Arterial Thrombosis in Pulmonary Arterial Hypertension: Diagnostic Differentiation, Imaging Criteria, and Management-A Narrative Review with an Institutional Case-Series Snapshot: In situ PAT in PAH: Imaging & Management.
Pulmonary arterial hypertension (PAH) creates a prothrombotic environment that may result in in situ pulmonary arterial thrombosis (PAT), a subtype that can resemble pulmonary embolism and chronic thromboembolic pulmonary hypertension (CTEPH) but requires different management. We conducted a narrative review of epidemiology, mechanisms, diagnostic differentiation, imaging (CT pulmonary angiography [CTPA], ventilation-perfusion [V/Q] scanning, echocardiography), and treatment of in situ PAT, and incorporated an institutional retrospective series (screened 2020-2025). In situ PAT typically appears on CTPA as central or wall-adherent thrombi within markedly dilated proximal pulmonary arteries, often without stenosis. Early V/Q scanning is useful to rule out CTEPH; non-segmental or mottled perfusion favors Group 1 PAH. Caliber metrics (PA diameter, PA/Ao) and RV strain indices (RV/LV, TAPSE) support but do not by themselves establish the diagnosis. Of 364 PAH patients screened, 7 (1.9%) met imaging criteria for in situ PAT; mean age 42 years, 71% female, 43% congenital heart disease. All had PA ≥30 mm and RV/LV ≥1; 71% had aneurysmal PA ≥40 mm; 71% had negative DVT Doppler. Functional and hemodynamic impairment was substantial. A stepwise workflow-DVT assessment, V/Q to exclude CTEPH, and targeted CTPA morphology interpreted with hemodynamics-facilitates accurate classification of in situ PAT and avoids misdirected CTEPH interventions. Therapy should begin with PAH-targeted treatment; anticoagulation should be individualized according to phenotype, bleeding risk, and clinical course.
- 14 November 2025
- p. 103209
In situ Pulmonary Arterial Thrombosis in Pulmonary Arterial Hypertension: Diagnostic Differentiation, Imaging Criteria, and Management-A Narrative Review with an Institutional Case-Series Snapshot: In situ PAT in PAH: Imaging & Management.
Pulmonary arterial hypertension (PAH) creates a prothrombotic environment that may result in in situ pulmonary arterial thrombosis (PAT), a subtype that can resemble pulmonary embolism and chronic thromboembolic pulmonary hypertension (CTEPH) but requires different management. We conducted a narrative review of epidemiology, mechanisms, diagnostic differentiation, imaging (CT pulmonary angiography [CTPA], ventilation-perfusion [V/Q] scanning, echocardiography), and treatment of in situ PAT, and incorporated an institutional retrospective series (screened 2020-2025). In situ PAT typically appears on CTPA as central or wall-adherent thrombi within markedly dilated proximal pulmonary arteries, often without stenosis. Early V/Q scanning is useful to rule out CTEPH; non-segmental or mottled perfusion favors Group 1 PAH. Caliber metrics (PA diameter, PA/Ao) and RV strain indices (RV/LV, TAPSE) support but do not by themselves establish the diagnosis. Of 364 PAH patients screened, 7 (1.9%) met imaging criteria for in situ PAT; mean age 42 years, 71% female, 43% congenital heart disease. All had PA ≥30 mm and RV/LV ≥1; 71% had aneurysmal PA ≥40 mm; 71% had negative DVT Doppler. Functional and hemodynamic impairment was substantial. A stepwise workflow-DVT assessment, V/Q to exclude CTEPH, and targeted CTPA morphology interpreted with hemodynamics-facilitates accurate classification of in situ PAT and avoids misdirected CTEPH interventions. Therapy should begin with PAH-targeted treatment; anticoagulation should be individualized according to phenotype, bleeding risk, and clinical course.
- 30 May 2025
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (2) , 685-692
Saddle pulmonary embolism: results of a series of patients undergoing pharmaco-mechanical thrombolysis
This study aimed to evaluate the clinical presentation and outcomes of patients with saddle pulmonary embolism (SPE) undergoing pharmaco-mechanical thrombolysis, highlighting the role of specialized multidisciplinary care. This retrospective study describes a series of cases in a Mexican tertiary care hospital with a newly established Pulmonary Embolism Rapid Response Team (PERT). The study took place in a tertiary care hospital in Mexico. Patients or participants: Twelve patients diagnosed with saddle pulmonary embolism were included in the study. All patients underwent catheter-guided thrombolysis and fragmentation as part of their treatment. The main variables of interest included clinical presentation, hemodynamic stability, and outcomes following catheter-directed therapy. Catheter-guided thrombolysis and fragmentation led to significant hemodynamic improvement in all patients. The intervention, combined with standard anticoagulation, showed promise in stabilizing hemodynamics and reducing thrombus burden, potentially improving outcomes in patients with SPE. Specialized multidisciplinary care, as provided by a Pulmonary Embolism Rapid Response Team, is crucial in managing saddle pulmonary embolism. The study offers insights into the safety and efficacy of endovascular interventions in this patient population.
- 30 May 2025
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 21 (2) , 685-692
Saddle pulmonary embolism: results of a series of patients undergoing pharmaco-mechanical thrombolysis
This study aimed to evaluate the clinical presentation and outcomes of patients with saddle pulmonary embolism (SPE) undergoing pharmaco-mechanical thrombolysis, highlighting the role of specialized multidisciplinary care. This retrospective study describes a series of cases in a Mexican tertiary care hospital with a newly established Pulmonary Embolism Rapid Response Team (PERT). The study took place in a tertiary care hospital in Mexico. Patients or participants: Twelve patients diagnosed with saddle pulmonary embolism were included in the study. All patients underwent catheter-guided thrombolysis and fragmentation as part of their treatment. The main variables of interest included clinical presentation, hemodynamic stability, and outcomes following catheter-directed therapy. Catheter-guided thrombolysis and fragmentation led to significant hemodynamic improvement in all patients. The intervention, combined with standard anticoagulation, showed promise in stabilizing hemodynamics and reducing thrombus burden, potentially improving outcomes in patients with SPE. Specialized multidisciplinary care, as provided by a Pulmonary Embolism Rapid Response Team, is crucial in managing saddle pulmonary embolism. The study offers insights into the safety and efficacy of endovascular interventions in this patient population.
- Open Access
- 27 November 2024
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 92 (6) , 485-503
Molecular Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Update from a Basic Research Perspective
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe condition characterized by persistent obstruction and vascular remodeling in the pulmonary arteries following an acute pulmonary embolism (APE). Although APE is a significant risk factor, up to 25% of CTEPH cases occur without a history of APE or deep vein thrombosis, complicating the understanding of its pathogenesis. Herein, we carried out a narrative review discussing the mechanisms involved in CTEPH development, including fibrotic thrombus formation, pulmonary vascular remodeling, and abnormal angiogenesis, leading to elevated pulmonary vascular resistance and right heart failure. We also outlined how the disease’s pathophysiology reveals both proximal and distal pulmonary artery obstruction, contributing to the development of pulmonary hypertension. We depicted the risk factors predicting CTEPH, including thrombotic history, hemostatic disorders, and certain medical conditions. We finally looked at the molecular mechanisms behind the role of endothelial dysfunction, gene expression alterations, and inflammatory processes in CTEPH progression and detection. Despite these insights, there is still a need for improved diagnostic tools, biomarkers, and therapeutic strategies to enhance early detection and management of CTEPH, ultimately aiming to reduce diagnostic delay and improve patient outcomes.
- 27 November 2024
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 92 (6) , 485-503
Open AccessMolecular Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Update from a Basic Research Perspective
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe condition characterized by persistent obstruction and vascular remodeling in the pulmonary arteries following an acute pulmonary embolism (APE). Although APE is a significant risk factor, up to 25% of CTEPH cases occur without a history of APE or deep vein thrombosis, complicating the understanding of its pathogenesis. Herein, we carried out a narrative review discussing the mechanisms involved in CTEPH development, including fibrotic thrombus formation, pulmonary vascular remodeling, and abnormal angiogenesis, leading to elevated pulmonary vascular resistance and right heart failure. We also outlined how the disease’s pathophysiology reveals both proximal and distal pulmonary artery obstruction, contributing to the development of pulmonary hypertension. We depicted the risk factors predicting CTEPH, including thrombotic history, hemostatic disorders, and certain medical conditions. We finally looked at the molecular mechanisms behind the role of endothelial dysfunction, gene expression alterations, and inflammatory processes in CTEPH progression and detection. Despite these insights, there is still a need for improved diagnostic tools, biomarkers, and therapeutic strategies to enhance early detection and management of CTEPH, ultimately aiming to reduce diagnostic delay and improve patient outcomes.
- 10 September 2024
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (12) , 102840
Updated review on pulmonary arterial hypertension: Differences between down syndrome and non-down syndrome populations
- 10 September 2024
- Published by Elsevier in Current Problems in Cardiology
- Vol. 49 (12) , 102840
Updated review on pulmonary arterial hypertension: Differences between down syndrome and non-down syndrome populations
- 1 October 2017
- Published by Elsevier in Revista Iberoamericana de Micologia
- Vol. 34 (4) , 233-236
Mucormicosis pulmonar en un paciente con trasplante renal y hemoptisis incoercible
- 1 October 2017
- Published by Elsevier in Revista Iberoamericana de Micologia
- Vol. 34 (4) , 233-236
Mucormicosis pulmonar en un paciente con trasplante renal y hemoptisis incoercible